Thyrocare Technologies Ltd vs Transgene Biotek Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 24, 2026

Key Highlights

The Latest Trading Price of Thyrocare Technologies Ltd is ₹ 462.25 as of 23 Oct 15:30 . The P/E Ratio of Thyrocare Technologies Ltd changed from 42.2 on March 2021 to 34.2 on March 2026 . This represents a CAGR of -3.44% over 6 yearsThe P/E Ratio of Transgene Biotek Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Thyrocare Technologies Ltd changed from ₹ 4774 crore on March 2021 to ₹ 5566 crore on March 2026 . This represents a CAGR of 2.59% over 6 yearsThe Market Cap of Transgene Biotek Ltd changed from ₹ 34.7 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The revenue of Thyrocare Technologies Ltd for the Jun '26 is ₹ 244.88 crore as compare to the Mar '26 revenue of ₹ 228.84 crore. This represent the growth of 7.01% The revenue of Transgene Biotek Ltd for the Jun '26 is ₹ 0.06 crore as compare to the Mar '26 revenue of ₹ 0.2 crore. This represent the decline of -70% The ebitda of Thyrocare Technologies Ltd for the Jun '26 is ₹ 82.13 crore as compare to the Mar '26 ebitda of ₹ 79.98 crore. This represent the growth of 2.69% The ebitda of Transgene Biotek Ltd for the Jun '26 is ₹ -0.06 crore as compare to the Mar '26 ebitda of ₹ -0.13 crore. This represent the decline of -53.85% The net profit of Thyrocare Technologies Ltd changed from ₹ 23.94 crore to ₹ 51.33 crore over 9 quarters. This represents a CAGR of 40.35% The net profit of Transgene Biotek Ltd changed from ₹ 0.2 crore to ₹ -0.39 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Thyrocare Technologies Ltd changed from 110.36 % on March 2021 to 149.75 % on March 2026 . This represents a CAGR of 5.22% over 6 yearsThe Dividend Payout of Transgene Biotek Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Thyrocare Technologies Ltd

Thyrocare Technologies Limited was incorporated in January, 2000.
The Company operates in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India. As of 31 March 2025, the Company offered more than 920 distinct tests that support early detection, preventive care and the ongoing disease monitoring.
Their 43 profiles are administered under its reputed 'Aarogyam' brand, which offers patients a suite of wellness and preventive health care tests.
The Company primarily operates its testing services through a fully automated Centralised Processing Laboratory (the CPL) and has expanded its operations to include a network of Regional Processing Laboratories (RPLs).
The company currently operates 25 RPLs, one in each of New Delhi, Coimbatore, Hyderabad, Kolkata, Bangalore, Bhopal, Mumbai Patna and Chennai, which process samples sourced from their respective regions.

About Transgene Biotek Ltd

Founded in March 1990 by Dr. Koteswara Rao, Transgene Biotek Limited was one of the first Biotechnology companies in India.
Although Transgene began life manufacturing and selling diagnostic kits, it soon moved on to true biotech research, including the research and development of vaccines, oncology , New drug delivery technologies etc.
The first major success came when it sold genetically engineered recombinant Hepatitis B vaccine technology along with novel and patented process in 1999 to the Serum Institute, Pune. Presently, the Company is engaged in the business of research and development and manufacture of various medical reagents, both chemical and immuno-diagnostic reagents for qualitative and quantitative estimation of bio-chemical parameters and diagnosis of diseases respectively.

FAQs for the comparison of Thyrocare Technologies Ltd and Transgene Biotek Ltd

Which company has a larger market capitalization, Thyrocare Technologies Ltd or Transgene Biotek Ltd?

Market cap of Thyrocare Technologies Ltd is 7,357 Cr while Market cap of Transgene Biotek Ltd is 19 Cr

What are the key factors driving the stock performance of Thyrocare Technologies Ltd and Transgene Biotek Ltd?

The stock performance of Thyrocare Technologies Ltd and Transgene Biotek Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Thyrocare Technologies Ltd and Transgene Biotek Ltd?

As of October 24, 2026, the Thyrocare Technologies Ltd stock price is INR ₹462.25. On the other hand, Transgene Biotek Ltd stock price is INR ₹2.57.

How do dividend payouts of Thyrocare Technologies Ltd and Transgene Biotek Ltd compare?

To compare the dividend payouts of Thyrocare Technologies Ltd and Transgene Biotek Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.